Skip to main content

IDBS Leads Consortium Building Platform for Stratified, Translational Medicine

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – IDBS today announced that it is developing an informatics platform to support stratified and translational medicine research and cross-organization collaboration.

The UK-based data management, analytics, and solutions firm was chosen by the Technology Strategy Board for the project, and will head a consortium called Tumor Profiling and Data Capture. Hosting firm Quantix and cancer centers at Kings Health Partners and Manchester Academic Health Science Center are also part of the consortium.

The platform being developed, called Advanced Collaborative Research for Oncology Platform for Improved Outcomes, Learnings, Insight, and Sciencer( ACROPOLIS), will provide a cancer informatics infrastructure to support secure stratified medicine research and collaboration, including data handling, storage, retrieval, and analysis services.

According to IDBS, ACROPOLIS will enable medical centers, pharmaceutical research, diagnostic companies, and other health science organizations to identify patient populations and better understand the genetics of cancer.

The consortium is being provided £3 million ($4.9 million) in funding, half from the Technology Strategy Board, as part of the UK's Stratified Medicines Innovation Platform (SMIP), and half from commercial partners.

The advisory board for the ACROPOLIS project includes Peter Parker, head of cancer studies at King's College London; Tony Whetton, head of cancer and enabling sciences at Manchester University; and representatives from Quantix, Roche Pharmaceutical, Cancer Research UK, PA Consulting, and the National Institute of Health Research.

"This innovative platform will put translational research activities onto another level, providing unprecedented opportunities to collaborate between organizations, and ultimately leading to improved treatments across global healthcare systems," Parker said in a statement.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.